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1. Introduction 
TSC (OMIM#191100) is an autosomal dominant disorder characterized by a broad 
phenotypic spectrum including epilepsy, mental retardation, skin lesions and tumors in 
various organs. The broad phenotypic spectrum reflected the development of hamartomas 
in multiple organs throughout the body (Schwartz et al., 2008). The incidence of TSC has 
been reported to be 1 in approximately 6000 (Osborne et al., 1991). However, its true 
incidence is not known because of a number of undiagnosed cases consisting mostly of 
mildly affected or asymptomatic individuals (Osborne et al., 1991). 
Two-thirds of TSC patients have sporadic mutations and only about one-thirds is familial. 
The genes in which abnormalities are found are called TSC1 and TSC2. Both genes have 
been studied by multigenerational linkage analysis (Fryer et al., 1987 and Kandt et al., 1992). 
TSC1 is located at position 9q34, and encodes a protein called hamartin, with an mRNA 
transcript of 8.6 kb containing 23 exons and encompassing 55 kb of DNA (van Slegtenhorst 
et al., 1997). TSC2 is located at position 16p13.3, and encodes a protein called tuberin, with 
an mRNA transcript of 5.5 kb, containing 41 exons and encompassing 40 kb of DNA (Eur TS 
Consortium, 1993).   
2. Clinical diagnosis of tuberous sclerosis complex 
There are major and minor clinical features (Table 1) that enable clinicians to clinically 
diagnose TSC. The clinical diagnosis is made when two major features, or one major and two 
minor ones, can be shown (Table 2). Sometimes, an antenatal diagnosis can be made based on 
fetal ultrasound and MRI, which show cardiac and brain lesions (Roach et al., 1998).  
Most patients are diagnosed in infancy or early childhood. A definitive diagnosis of TSC 
can be made when two major features or one major feature plus two minor features are 
demonstrated (Hyman, 2000 and Roach, 1998). Additional diagnostic categories include 
probable TSC when one major feature and one minor feature are present, and possible TSC 
when either one major feature or two or more minor features are present (Hyman, 2000 and 
Roach, 1998). However, as hamartomas are individually rare in the population without TSC, 
the presence of hamartomas in two different organ systems is considered by some clinicians 
to be sufficient for the diagnosis (O’Callaghan, 2000). 
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MAJOR FEATURES MINOR FEATURES 
Features Description 
Diagnosis, 
location 
Age of 
onset 
Prevalence Features Description 
Diagnosis, 
location 
Preva-
lence 
Facial 
angiofibromas 
or forehead 
plaque 
(Schwartz et al., 
2007)  
Red to pink papules 
with a smooth 
surface, 
symmetrically 
distributed over the 
centrofacial areas, 
sparing the upper 
lips 
Histologic 
(head) 
Second 
to fifth 
year of 
life; 
more 
promi-
nent with 
age 
74.5% 
Multiple, 
randomly 
distributed 
pits in 
dental 
enamel 
(Mennel et 
al., 2007) 
 
Dental pits are 
pits in the enamel 
of the permanent 
teeth. They occur 
more frequently 
in individuals 
with TSC than in 
people who do 
not have TSC. 
Direct inspection 
of the labial 
surfaces of the 
incisor and 
canine teeth 
48 - 
100%. 
Non-traumatic 
ungula or 
periungual 
fibroma 
(Schwartz et al., 
2007) 
Skin-colored or 
reddish nodules seen 
on the lateral nail 
groove, nail plate, or 
along the proximal 
nail folds; more 
commonly found on 
the toes than on the 
fingers 
Histologic 
(fingers and 
toes) 
Puberty 
or soon 
after; 
more 
common 
with age 
15.1% 
Hamarto-
matous 
rectal 
polyps 
(Young & 
Povey, 
1998) 
These polyps are 
common and do 
not cause 
symptoms. Their 
distinctive 
appearance and 
distribution readily 
distinguish them 
from other types of 
rectal polyp and 
emphasize their 
importance as a 
potentially useful 
clinical marker of 
TSC
Histologic 
(rectum) 
78%  
Hypomelanotic 
macules (three 
or more) 
(Schwartz et al., 
2007) 
Leaf-shaped or 
polygonal white 
spots, enhanced by 
Wood’s lamp 
examination; more 
common on the 
trunk and buttocks 
Histologic 
(skin) 
At birth 
or 
infancy 
Earliest 
cuta-
neous 
lesion 
appeared
 
 
97.2% 
Cerebral 
white 
matter 
radial (Xu 
et al., 1996)
Most lesions are 
best seen on 
proton density-
weighted images 
as bright spots.  
MRI (brain) 15% 
Shagreen patch 
(connective 
tissue nevus) 
(Schwartz et al., 
2007)   
Slightly elevated 
patch or plaque, 
usually found on the 
dorsal body surfaces, 
especially the 
lumbosacral area; its 
rough surface 
resembles an orange 
peel. Represents a 
connective tissue 
nevus, sometimes 
called collagenoma 
Histologic 
(skin) 
Rare 
during 
infancy, 
tend 
to 
increase 
in size 
and 
number 
with age 
48.1% 
Gingival 
fibromas 
(Mennel et 
al., 2007) 
These small 
fibrous nodules of 
the oral cavity are 
most commonly 
evident on the 
gingiva, especially 
in the anterior 
segment of the 
upper jaw but also 
on the buccal 
mucosa and 
dorsal surface of 
the tongue. 
Oral (gums) 32% 
Multiple retinal 
nodular 
hamartomas 
(Xu et al., 1995) 
Retinal hamartoma is 
a common finding in 
tuberous sclerosis, 
but the symptomatic 
changes of this lesion 
have rarely been 
described. 
Ocular 
(eyes) 
Infancy 9.7% 
Non-renal 
hamarto-
ma 
(Mennel et 
al., 2007) 
Homartomatous 
formation in other 
organs than the 
kidney.  
Histologic     
( Liver, spleen) 
 
Cortical tuber 
(Mennel et al., 
2007)  
Cortical tubers are the 
most characteristic 
lesions of tuberous 
sclerosis at pathologic 
examination. Varying 
in size from 
millimeters to several 
centimeters, tubers 
are rounded or wart-
like protrusions of 
single or adjacent 
gyri, very firm to 
touch and pale in 
color 
MRI (brain)
During 
fetus 
develop-
ment 
95% 
Retinal 
achromic 
patch 
(Mennel et 
al., 2007) 
Greyish or 
yellowish-white 
lesion in the back 
of the globe on the 
ophthalmic 
examination.  
A differential 
diagnosis for a 
calcified globe 
mass on a CT 
scan. 
CT Scan (eyes) 12% 
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MAJOR FEATURES MINOR FEATURES 
Features Description 
Diagnosis, 
location 
Age of 
onset 
Prevalence Features Description 
Diagnosis, 
location 
Preva-
lence 
Subependymal 
nodule (Mennel 
et al., 2007)  
Occur in the third 
and fourth 
ventricular walls, but 
most are found in the 
lateral ventricular 
walls, near the sulcus 
terminalis, with their 
deeper parts 
embedded in the 
caudate or thalamus.
MRI (brain)
 
Increases 
with the 
age of 
the 
patient 
 
 
95% 
Confetti-
like skin 
lesions 
(Mennel et 
al., 2007) 
Multiple, 1-2 mm 
white spots 
symmetrically 
distributed over 
extremities 
Histologic  
(skin) 
2.8% 
SEGA (Mennel 
et al., 2007) 
(SEGAs) 
This type of tumor 
develops in 
approximately 15% 
of individuals with 
tuberous sclerosis. 
Typically, SEGAs do 
not occur in very 
young children, and 
the chance for their 
growth decreases 
after age 20. 
Radio-
graphy 
(brain) 
Child to 
adole-
scent 
15% 
Multiple 
renal cysts 
(Inoue, 
1998) 
Like AMLs, they 
are frequently 
multiple and 
bilateral. 
However, renal 
cysts are more 
likely to become 
symptomatic than 
AMLs. Polycystic 
kidney disease 
may also occur. It 
is a more severe, 
distinct entity 
with innumerable 
cysts that enlarge, 
replace renal 
parenchyma, and 
cause renal 
insufficiency and 
hypertension 
typically at an 
early age 
Histologic 
(kidney) 
17% 
(children) 
47% 
(adults) 
Cardiac 
rhabdomyoma, 
single or 
multiple 
Rhabdomyomas are 
benign tumors of 
striated muscle 
Echocardio-
graphy  
Grow 
during 
the 
second 
half of 
preg-
nancy 
and 
regress 
after 
birth 
90% 
(newborn) 
20% (adult)
    
Lymphangio 
myomatosis 
(Schwartz et al., 
2007) 
Rare lung disease 
that results in a 
proliferation of 
disorderly smooth 
muscle growth 
(leiomyoma) 
throughout the 
bronchioles,  
alveolar septa, 
perivascular 
spaces, and 
lymphatics 
Histologic 
(lung) 
Adole-
scent to 
adult 
49%     
Renal 
angiomyolipom
a (Schwartz et 
al., 2007) 
Renal 
angiomyolipoma is a 
benign neoplasm 
that may grow 
massive in TSC 
patients. 
Histologic 
(kidneys) 
Adole-
scent to 
adult 
80%     
Table 1. Major and Minor Features of Tuberous Sclerosis Complex. 
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Clinical Diagnosis Characteristic 
Definite TSC Either two major features or one major plus two minor 
features 
Probable TSC One major plus one minor features 
Possible TSC Either one major features or two or more minor features 
Table 2. Clinical Diagnosis of TSC. There are several differential diagnosis of TSC : 
a. Multiple Endocrine Neoplasia type I (MEN-I) in which multiple angiofibromas, 
confetti-like hypopigmented macules, and multiple gingival papules are also seen. 
b. Hypopigmented macules in TSC resemble nevus anemicus and nevus depigmentosus. 
c. Renal Carcinoma may also be caused by mutations within VHL (cause VHL disease) or 
MET (cause HPRC) genes, although with different pathologic findings. The renal cell 
carcinomas in TSC are morphologically heterogenous, including clear cell, papillary, 
and chromophobic tumors. VHL patients almost exclusively develop clear cell 
carcinoma, while HPRC patients develop almost exclusively papillary tumors. 
3. Epilepsy in tuberous sclerosis complex 
Epilepsy was once included in tuberous sclerosis triad along with mental retardation and 
adenoma sebaceum (Provenzale, 1991). Although removed from the diagnostic criteria, 
epilepsy remains a dominant feature in tuberous sclerosis, covering up to 60% - 90% of TSC 
cases. Genetic factors play important contributions in the manifestation of epilepsy in TSC. 
It has recently been described that inactivation of TSC2 causes more severe epilepsy 
phenotype than inactivation of TSC1 in a mouse model of tuberous sclerosis and suggested 
that the difference in phenotype may be related to the degree to which TSC1 and TSC2 
inactivation causes abnormal mTOR activation (Zheng, 2010).  
Based on clinical features alone, TSC patients may experience a wide variety of ictal 
symptoms. Two syndromes are usually noted: infantile spasms (Christophea et al., 2000), 
which then evolve into partial or mixed epilepsies (Dabora et al., 2001) and partial seizures, 
typically starting later in childhood. The high incidence of infantile spasms in TSC has long 
been emphasized. Infantile spasms have been reported to be the presenting symptoms in up 
to 69% of patients with TSC. Infantile spasms in TSC usually have their onset between 4 to 6 
months of age (Curatolo et al., 2001 and Fukushima et al 2001). TSC has been found in 7%– 
25% of infants with symptomatic West syndrome. West syndrome classically consists of the 
clinical-electroencephalographic triad of spasms (the seizure type), hypsarrhythmia and 
mental deficiencies. The main types of spasms (flexor, extensor, mixed) may occur in infant 
with TSC, but focal features such as head turning, nystagmus, tonic eye deviation or 
unilateral limb movement differentiate them from classical infantile spasms. Partial seizures 
predominate with the increasing age (Curatolo, 2001 and Jambeque et al., 1991). 
Location of tubers on MRI often correlates with EEG discharges. Tubers consist of dysplastic 
neurons and glial cells that distort the normal cortical architecture, causing them to be 
highly epileptogenic (Christopher et al., 2000). Jambaque and collegues found that an initial 
presentation with infantile spasms, refractory seizures and mental retardation or behaviour 
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disorder were all more likely in children with greater numbers of cortical tubers. The classic 
interictal EEG pattern of patients with epileptic spasm is hypsarrhythmia. Hypsarrhythmia 
was originally defined by Gibbs and Gibbs in 1950 as completely chaotic and disorganized 
background pattern consisting of high amplitude slow waves and spikes that are 
asynchronous, non-rhythmic and variable in duration and topography. The spikes usually 
alternate randomly between focal, multifocal and generalized discharges at different 
moments within a brief record. It is most pronounced in slow-wave sleep. Ictal recordings of 
spasms can demonstrate a focal increase in spikes and polyspikes at the onset, with an 
abrupt generalized slow followed by electro decrement or generalized lower amplitude fast 
activity coincident with the spasm itself. Curatolo has theorized the following sequence of 
events. Electrographic onset of spasms is more common from the posterior temporal and 
occipital regions than from other locations. Subsequent partial seizures tend to arise from 
the frontal or anterior temporal regions. 
Drug selection should be tailored to both clinical and EEG attributes observed. Antiepileptic 
drug monotherapy is used whenever possible.  Vigabatrin may be especially effective for 
infantile spasms in patients with TSC, with some series reporting complete control occurring 
in about 95% of patients (Aicardi, 1996 and Hancock, 1999). Vigabatrin produces its 
antiepileptic effect by irreversibly inhibiting the enzyme GABA-aminotransferase. This 
results in increased brain and spinal fluid concentration of the inhibitory neurotransmitter 
GABA. Unfortunately, recent reports of visual-field constriction associated with vigabatrin 
therapy may limit its use and may prevent from becoming an approved treatment in United 
States and other countries (Krauss et al., 1998). Other evidence from randomized controlled 
studies includes using ACTH and corticosteroids for infantile spasms. Chronic use of 
benzodiazepines and barbiturates should be avoided if possible owing to their cognitive and 
behavioural adverse effects. Other medications useful to treat seizures in TSC include 
lamotrigine, felbamate, topiramate, carbamazepine and levetiracetam. When anticonvulsant 
options have been exhausted, alternative treatment such as ketogenic diet may be tried. If 
severely disabling seizures are present with consistent electroclinical and imaging data 
suggesting a confined area of seizure onset, surgical treatment should be considered. The 
most common surgical procedures offered to TSC patient include topectomies, gyrectomies 
or wider lobar resection as well as multiple subpial transection. Vagal nerve stimulation is a 
surgical option restricted to TSC patients with intractable epilepsy who fail to meet the 
criteria for resective surgery. 
4. Molecular diagnosis of tuberous sclerosis complex 
Despite the comprehensive criteria for clinical diagnosis of TSC, molecular analyses of both 
causing genes remain of importance. Mutation analysis in TSC patients is useful 1) to 
confirm a clinical diagnosis of TSC, especially in young patients in whom many clinical 
features have yet to develop, 2) in families with sporadic cases of TSC, mutation analysis 
may provide reassurance that the rest of the family members do not carry the mutation. 
However, such testing does not provide complete reassurance in regard to the possibility of 
having the second child with TSC, even when the parents do not appear to carry the 
mutation, and 3) to perform prenatal diagnosis, in families with either a child or a parent 
with a known mutation.  
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5. TSC1 and TSC2 genes variation spectrum 
Table 3 and 4 summarized updates on the variation spectrum within TSC1 and TSC2 and 
review their characteristics. The information was accessed from the LOVD for Tuberous 
Sclerosis (http://chromium.liacs.nl/LOVD2/TSC/ home.php) on 3 April 2011 (Fokkema et 
al, 2005). There are 468 unique TSC1 sequence variations and 1222 unique TSC2 sequence 
variations reported. Tables 1 and 2 listed up all unique sequence variations of TSC1 and 
TSC2 respectively, along with their variation types and information of pathogenicity.  
 
                               Types 
 
 
Pathogenicity (R/C)* 
 
Substitution
 
Insertion
 
Deletion
 
Duplication
 
Insertion / 
Deletion 
 
Total 
-/- 12 Nil Nil 1 Nil 13 
-/-? Nil 1 2 1 Nil 4 
-/? 1 Nil Nil Nil Nil 1 
-/+? 1 Nil Nil Nil Nil 1 
-?/- 1 Nil Nil Nil Nil 1 
-?/-? 9 Nil Nil Nil Nil 9 
-?/? 6 Nil Nil Nil Nil 6 
-?/+? 1 Nil Nil Nil Nil 1 
?/- 5 Nil Nil Nil Nil 5 
?/-? 5 Nil Nil Nil Nil 5 
?/? 23 Nil Nil Nil Nil 23 
?/+? 2 Nil 1 Nil Nil 3 
?/+ Nil Nil Nil 1 Nil 1 
+?/? 5 Nil 2 Nil Nil 7 
+?/+? 4 Nil Nil Nil Nil 4 
+?/+ 2 Nil Nil 1 Nil 3 
+/- 4 Nil Nil Nil Nil 4 
+/? 3 1 3 Nil 1 8 
+/+? 16 Nil 7 2 Nil 25 
+/+ 133 12 146 51 2 344 
Total 233 14 161 57 3 468 
*R/C = Reported/Concluded. "Reported Pathogenicity" refers to the pathogenicity as published by the 
authors in the original paper or as submitted to the LOVD-TSC database if the data has not been 
published. "Concluded Pathogenicity" refers to the pathogenicity that the curators of the database have 
assigned to the variant. (Personal Communication with the LOVD-TSC Database Curator; Dr. Rosemary 
Ekong). “-“ = no known pathogenicity;    “-?” = probably no pathogenicity; “+” = pathogenic; “+?” = 
probably pathogenic; “?” = unknown pathogenicity.  
Table 3. TSC1 sequence variations and their pathogenicity.   
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                       Types 
 
 
Pathogenicity (R/C)* 
 
Substitution
 
Insertion
 
Deletion
 
Duplication
 
Insertion / 
Deletion 
 
Total 
-/- 154 2 8 6 1 171 
-/-? 42 1 2 2 Nil 47 
-/? 96 Nil Nil Nil Nil 96 
-/+? 1 Nil Nil Nil Nil 1 
-?/- 7 Nil Nil Nil Nil 7 
-?/-? 14 Nil Nil Nil Nil 14 
-?/? 1 Nil Nil Nil Nil 1 
?/- 5 Nil 1 Nil Nil 6 
?/-? 17 Nil 1 Nil Nil 18 
?/? 46 1 5 3 1 56 
?/+? 13 Nil 1 Nil Nil 14 
?/+ 13 Nil 4 2 Nil 19 
+?/? 15 1 1 1 1 19 
+?/+? 19 1 6 Nil Nil 26 
+?/+ 1 1 5 1 1 9 
+/- 6 Nil 2 Nil Nil 8 
+/? 22 Nil 5 3 Nil 30 
+/+? 60 2 16 3 7 88 
+/+ 303 33 148 103 Nil 587 
-/+ 1 Nil 1 Nil Nil 2 
+?/- 1 Nil Nil Nil Nil 1 
+?/-? 1 Nil Nil Nil Nil 1 
+/-? 1 Nil Nil Nil Nil 1 
Total 839 42 206 124 11 1222 
*R/C = Reported/Concluded. "Reported Pathogenicity" refers to the pathogenicity as published by the 
authors in the original paper or as submitted to the LOVD-TSC database if the data has not been 
published. "Concluded Pathogenicity" refers to the pathogenicity that the curators of the database have 
assigned to the variant. (Personal Communication with the LOVD-TSC Database Curator; Dr. Rosemary 
Ekong). “-“ = no known pathogenicity;    “-?” = probably no pathogenicity; “+” = pathogenic; “+?” = 
probably pathogenic; “?” = unknown pathogenicity. 
Table 4. TSC2 sequence variations and their pathogenicity.   
In TSC1, the most prevalent types of variations found are substitution (49.8%) followed by 
deletion (34.4%). Of 468 unique variations reported in TSC1, 73.5% (344) had their 
pathogenicity determined. In TSC2, the most prevalent types of variations found are also 
substitution (68.7%) followed by deletion (16.9%). Of 1222 unique variations reported in 
TSC2, only less than half (48%) had their pathogenicity determined. Different gene sizes of 
TSC1 and TSC2 may explain the fact that more variations occurred in TSC2 than in TSC1. 
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Perhaps because of more chances of the variations to occur along considerable length of 
intronic portions within TSC2, less pathogenicity variations can be conclusively determined.    
The tables showed that of 1690 TSC1 and TSC2 variations reported, only 27.7% (468) were 
found in TSC1. There are some explanations for the fact that up to date more TSC2 
variations were found compared to TSC1: 
a. According to Knudson’s hypothesis, loss of heterozygosity (LOH) of a tumor 
suppressor gene is necessary for tumor progression. Recent investigations of somatic 
mutations in a variety of TSC hamartomas support classification of the TSC genes as 
tumor suppressor genes. Loss of Heterozygosity (LOH) in TSC1 hamartomas are rare 
compared to that in TSC2 hamartomas (Cheadle et al., 2000). This may reflect the low 
frequency of TSC1 diseases.  
b. Several large studies reported that TSC1 mutations are presented with less severe 
phenotype than TSC2 mutations. In 1991, Osborne and colleagues outlined that although 
TSC incidence is reported as 1 in approximately 6000, the true incidence of TSC is not 
known because of a number of undiagnosed cases consisting mostly of mildly affected or 
asymptomatic individuals. It is probable that this portion of patients harbored TSC1 
mutations, accounting for the small number of TSC1 mutations found until today. 
c. TSC2 coding region is about 1.5 times longer than TSC1 and has approximately twice 
the number of splice sites, affording a proportionally increased opportunity for all 
manner of small mutations. 
6. Molecular pathogenesis of TSC 
Up to 85% of TSC cases are due to mutations in either TSC1 or TSC2 genes which lead to a 
truncated protein with a loss of function mechanism. Investigation of somatic mutations in a 
variety of TSC hamartomas supports classification of the TSC1 and TSC2 as tumor 
suppressor genes (Cheadle et al., 2000). Mutations in TSC1 and TSC2 affect neuronal 
proliferation, differentiation, and migration (Crino et al., 1999). The identification of the 
TSC1 and TSC2 genes and their encoded proteins, hamartin and tuberin respectively, has 
aided in understanding the molecular pathogenesis of TSC where hamartomatous formation 
is the outcome.  
Both hamartin and tuberin are widely expressed in normal tissues including brain, liver, 
and kidney. Hamartin is highly expressed in G0-arrested cells and throughout the ongoing 
cell cycle (Crino, 2004). Alterations in tuberin expression have been reported in patients with 
TSC. Immunoreactivity of tuberin is reduced in the brain with TSC. Loss of hamartin and 
tuberin formation due to TSC1 and TSC2 mutations can enhance proliferation of neural and 
astrocytic precursor cells and increased in cell size characteristic of dysplastic neurons and 
giant cells. When either of the TSC1 or TSC2 genes is inactivated, G1 is shortened and 
tissues become hypertropic (Potter et al., 2001). Over-expression of either hamartin or 
tuberin can lengthen G1 and inhibits cell proliferation (Tapon et al., 2001).  
Many studies indicated that hamartin and tuberin, encoded by TSC1 and TSC2 genes 
respectively, function as a complex. The complex has a stable interaction with stoichiometry 
of 1:1. The tight binding interaction between the two proteins formed a tumour suppressor 
heterodimer (Kwiatkowaki, 2008). Hamartin and tuberin have been found to physically 
associate with one another in vivo. Disruption in either one of the two genes may result in a 
truncated protein with the loss in controlling the cell growth and proliferation. The 130 kDa 
hamartin contains a putative transmembrane domain. Hamartin’s membrane bound protein 
www.intechopen.com
 
Tuberous Sclerosis Complex 
 
19 
and two coiled-coil domains are necessary for its association with tuberin (van Slegtenhorst 
et al., 1997 and van Slegtenhorst et al., 1998). 
Although TSC1- or TSC2-specific functions are possible, it seems that the predominant 
biochemical activity of these proteins is exerted by an equimolar complex, which regulates 
the state of GTP-loading of the rheb GTPase, and thereby regulates mTOR activation in the 
cell. As most hamartomas in TSC develop through a two-hit inactivation mechanisms 
(Knudson’s hypothesis for tumor suppressor genes, including TSC1 and TSC2), it appears 
likely that somatic mutations in TSC1 are less common than those in TSC2, just as the rate of 
germline mutation in TSC1 is much lower than that in TSC2. Thus, fewer and/or less severe 
clinical manifestations would be seen in TSC1 patients. 
LOH is very common within TSC hamartomas, except for cardiac or brain. In both organs, 
study says that wildtype hamartin and tuberin are present. LOH is an event by which 
within the affected cells, the genomic DNA loss its heterozygosity, becoming homozygous 
for the mutation. In other cells (unaffected cells) the genomic DNA shows heterozygous for 
the mutation. To analyze the occurrence of LOH it is necessary to perform mutation analysis 
on the genomic DNA extracted from the affected cells as well as from the unaffected cells. 
After the discovery of TSC1 and TSC2 and their encoded proteins, several downstream 
protein cascades that might be affected by the pathogenesis of the disease, such as the 
pathway of mTOR (mammalian target of rapamycin), were identified. 
 
 
Fig. 1. Hamartin and tuberin as tumor suppressor gene.  
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Figure 1 illustrated the roles of hamartin and tuberin in cell metabolism describing that 
disruption in either of both genes may result in loss of the control of cell growth and 
proliferation. Hamartin-tuberin complex inhibits the mTOR which is a key regulator in the 
signalling pathway of cell proliferation and organ size (Kwiatkowski, 2008). It has been 
reported that the complex regulates mTOR via hydrolysis of Rheb-GTP into its inactive GDP 
bound state, Rheb-GDP (Rosner et al., 2004 and Tee et al., 2003).  
Tuberin and hamartin form an intracellular complex which activates GTPase, reducing 
stimulation of mTOR. mTOR detects signals of nutrient availability, hypoxia, or growth 
factor stimulation, and is part of many cell processes, such as cell-cycle progression, 
transcription and translation control, and nutrient uptake. It phosphorylates, among other 
proteins, S6K1 and eukaryotic translation initiation factor 4E-BP1. S6K1 is a kinase that 
activates ribosomal subunit protein S6, leading to ribosome recruitment and protein 
translation. 4E-BP1 inhibits activity of eukaryotic translation initiation factor 4E (eIF4E) and, 
when phosphorylated by mTOR, releases eIF4E from its control. 
The complex inhibits mTOR by acting as a GAP toward Rheb, which promotes hydrolysis of 
Rheb-GTP, converting it to an inactive GDP bound state. Without its active GTP bound state, 
Rheb cannot stimulate mTOR-mediated signalling to downstream components S6K1 and 4E-
BP1. The mechanism is reversed with the presence of amino acids which activates Rheb-GEF. 
RhebGEF converts Rheb-GDP to its active Rheb-GTP and promotes mTOR signalling. Akt 
inactivates TSC tumor suppressor complex by phosphorylation of TSC2 (Tee et al., 2003). 
Common TSC2 mutations result in the loss of the GAP domain of tuberin through C-
terminal truncations, whereas some point mutations are clustered within the GAP domain. 
It is also reported that, an intact GAP domain of tuberin is crucial for association with 
hamartin in the formation of tuberin-hamartin heterodimers. The heterodimers will inhibit 
Rheb-induced mTOR signalling and can also function as a GAP toward Rheb. Higher 
proportion of the active GTP bound form of Rheb can likely be found within TSC patients. It 
is the result of non-functional tuberin-hamartin heterodimers where the genes failed to 
encodes for a functional protein (van Slegtenhorst et al., 1998). 
The 200kDa (1806 amino acids) tuberin is homologous to the GTPase activating proteins 
(GAP) rap1GAP and mSpa1 where it contains relatively hydrophobic N-terminal domain 
and conserved 163 amino acids region close to the C-terminus. Rap1GAP is the member of 
Ras-related protein and functions in regulation of DNA synthesis and cell-cycle transition. 
The GAP activity of functional tuberin can regulate the effects of Rap1 on G to S phase 
transition during cell division. Thus, it implies that TSC2 mutations may result in 
constitutive activation of Rap1 (Wienecke et al., 1996 and Wienecke et al., 1997). 
Tuberin also has been demonstrated to interact with rab5. Rab5 is a cytosolic protein, is an 
effector for the endosomal small GTPase and therefore involved in endocytic fusion events 
(Stenmark et all., 1995). Consistently with the finding, tuberin has also been shown to act as a 
GTPase activating protein for rab5 and reduce the fluid-phase endocytosis (Xiao et al., 1997). 
As for 130 kDa (1164 amino acids) hamartin, it has hydrophilic protein with no significant 
homology to tuberin or other known vertebrate protein. Van Slegtenhorst and colleagues 
have investigated the association between endogenous hamartin and tuberin and they 
found out that both proteins play a closely related role (van Slegtenhorst et al., 1998). The 
methods used in the study suggest that inactivation of hamartin and tuberin may prevent 
the formation of a functional protein complex. 
Hamartin was recently identified as an interactor with the cytoskeletal proteins, ERM family 
(Lamb et al., 2000). The function loss can alternatively compromise neural migration via 
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interaction with ERM or actin binding proteins. It was also shown to activate the GTPase 
Rho and regulates focal adhesion and stress fiber formation. Hamartin activates the GTPase 
Rho via the overlapping region of Rhos’s amino acid and hamartin’s tuberin-interaction 
domain (Lamb et al., 2000). The dysregulation of signalling by the Rho family of GTPase is 
said to have a critical role in cancer cell migration, invasion, and metastasis (Clark et al., 
2000; Evers et al., 2000; Royal et al., 2000 and Schmitz et al., 2000). 
It has also been recently shown that the functional complex interact with G2/M cyclin-
dependant kinase 1 and its regulatory cyclins. Thus, mutation in either both genes may alter 
the kinetics of cell divisions (Catania et al., 2001). The functional heteromeric complex of 
hamartin and tuberin also plays important role in modulating the pathways of insulin 
receptor-or insulin-like growth factor-mediated signalling. The pathway functions 
downstream of the cell signalling molecule Akt, also play roles in regulating cell growth and 
potentially cell size.  
7. Studies on therapeutics options for TSC 
At present, the management of TSC is symptomatic. Some of TSC manifestations have been 
subjected to drug therapies but they are still in the developmental stage (Yates et al., 2006). 
Table 5 summarized several drugs under investigation for their efficacy towards Tuberous 
Sclerosis Complex.  
The discovery of mTOR (mammalian target of rapamycin) pathway upregulation in 
tuberous-sclerosis-associated tumours presents new possibilities for treatment strategies. A 
TSC mouse treated with rapamycin, also known as sirolimus, was found to have its learning 
and memory deficits improved (Ehninger et al., 2008).  
Sirolimus is a macrolide antibiotic that acts as an mTOR kinase inhibitor. It is isolated from 
Streptomyces hygroscopicus. Sirolimus and its analogs have been shown to make the 
dysregulated mTOR pathway return to normal in cells that lack TSC1 or TSC2. Several 
results from in-vitro or in-vivo animal studies suggest that sirolimus or its analogues might 
be effective in the treatment of various manifestations of tuberous sclerosis such as skin 
lesions (Rauktys et al., 2008), lymphangioleiomyomatosis (Goncharova et al., 2006 and 
Bissler et al., 2008), renal angiomyolipomas (Lee et al., 2006; Herry et al., 2007 and Wienecke 
et al., 2006), renal-cell carcinoma (Robb et al., 2007), subependymal giant-cell astrocytomas 
(Franz et al., 2006) or even polycystic kidney disease (Weimbs et al., 2006).  
However, angiomyolipomas increased in volume after the therapy was discontinued, and 
some patients taking sirolimus experienced serious adverse events (Bissler et al., 2008; Herry 
et al., 2007 and Wienecke et al., 2006). 
Recently, other classes of drugs have also been found to be possible therapeutic options for 
TSC. Interferon gamma and interferon alpha interact with mTOR, leading to deactivation of 
the translational repressor 4E-BP1, which could be beneficial for the treatment of tuberous 
sclerosis (Kaur et al., 2007).  Other classes of drugs ranging from those which can alter 
amino acids metabolism, inhibit VEGF signalling and inhibit microtubules were also 
studied. Presence or absence of amino acids is an important regulator of mTOR pathway 
signalling (Avruch et al., 2006). 
For example, L-asparaginase, a hydrolase enzyme and one of the most important agents 
used in multidrug chemotherapy for the treatment of cancer. It is mainly used to treat 
human leukemic cells in acute lymphoblastic leukemic. L-asparaginase has been found to 
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Table 5. Potential drugs under investigations for the therapy of TSC. 
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reduce the levels of mTOR pathway’s target p70 S6 kinase and 4EBP-1 (Iiboshi et al., 1999). 
The reduction indicates that L-Asparaginase can be a possible therapeutic option for TSC. 
VEGF is thought to play important role in the pathogenesis of TSC since tumors associated 
with TSC are vascular. TSC2 has also been found to have association with increased levels of 
VEGF in cultured cells (Brogarolas et al., 2002). Since VEGF signalling is important in the 
TSC pathogenensis, combination of VEGF inhibitors with mTOR inhibitor analogs may 
provide a promising treatment. 
Sorafenib is one of VEGF inhibitors. It is an oral targeted kinase inhibitor that blocks VEGF-
R. In TSC tumor preclinical study by Lee and colleagues, combination of Sorafenib and 
Sirolimus was found more effective than single agent (Lee et al., 2009). Other VEGF inhibitor 
is Sunitinib which also inhibit platelet derived VEGF-R. It is a receptor tyrosine kinase 
inhibitor. Bevacizumab, a recombinant humanised monoclonal antibody, is also a VEGF-R 
inhibitor. Both Sunitinib and Bevacizumab produce inhibitory effects to VEGF-R signalling 
pathway and may be useful for TSC treatment. 
 
 
Fig. 2. Interaction of possible therapeutic options with various pathways in TSC 
pathogenesis (http://www.genome.jp/dbget-bin/www_bget?map04150). 
8. Abbreviations 
4E-BP1  : 4E Binding Protein 1 
ACTH  : adrenocorticotrophic hormone 
AML  : angiomyolipoma 
DNA  : deoxyribonucleidc acid 
EEG  : Electroencephalography 
ERM  : Exin-radixin-moesin 
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GABA  : gamma-aminobutyric acid 
kb  : kilobase pair 
LOH  : Loss of Heterozygosity 
LOVD  : Leiden Open Variation Database 
MRI  : Magnetic Resonance Imaging 
mRNA  : messenger ribonucleic acid 
mTOR  : mammalian target of rapamycin 
Rheb  : Ras homologue enriched in brain 
TSC  : Tuberous Sclerosis Complex 
TSC1  : Tuberous Sclerosis Complex gene 1 
TSC2  : Tuberous Sclerosis Complex 2 
VEGF  : vascular endothelial growth factor 
VEGF-R  : vascular endothelial growth factor receptor 
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